Finance

Lists
T1EV34:BVMF
Teva Pharmaceutical Industries Bdr
R$118.90
0.00%
(0.00) 1D
Nov 10, 4:56:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for T1EV34...
Open
R$118.90
High
R$118.90
Low
R$118.90
Mkt. cap
48.61B
Avg. vol.
44.00
Volume
1.00
52-wk high
R$118.90
52-wk low
R$65.94
Shares outstanding
1.17B
No. of employees
32K
Open
R$118.90
High
R$118.90
Low
R$118.90
Mkt. cap
48.61B
Avg. vol.
44.00
Volume
1.00
52-wk high
R$118.90
52-wk low
R$65.94
Shares outstanding
1.17B
No. of employees
32K
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Bdr
CEORichard Francis
Employees32K
FoundedFeb 13, 1944
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteteva.co.il
Last report
Nov 3, 2026
Fiscal period
Q3 2026
$0.86 / $0.72
+19.31%beat
Revenue / Est. (USD)
4.40B / 4.23B
+3.96%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
4.71B
3.98B
4.14B
4.40B
Cost of goods sold
2.06B
2.01B
1.99B
1.96B
Cost of revenue
2.06B
2.01B
1.99B
1.96B
Research and development expenses
267.00M
222.00M
970.00M
297.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.12B
1.00B
1.03B
1.01B
Operating expense
1.37B
1.21B
1.99B
1.24B
Total operating expenses
3.43B
3.22B
3.98B
3.19B
Operating income
1.28B
763.00M
167.00M
1.20B
Other non operating income
-
-13.00M
-69.00M
-22.00M
EBT including unusual items
90.00M
436.00M
-455.00M
300.00M
EBT excluding unusual items
1.08B
547.00M
-57.00M
1.01B
Income tax expense
-390.00M
67.00M
121.00M
66.00M
Effective tax rate
-433.33%
15.37%
-26.59%
22.00%
Other operating expenses
-17.00M
-14.00M
-18.00M
-68.00M
Net income
480.00M
369.00M
-576.00M
233.00M
Net profit margin
10.19%
9.27%
-13.91%
5.30%
Earnings per share
0.96
0.53
0.02
0.86
Interest and investment income
92.00M
-
-
-
Interest expense
-280.00M
-191.00M
-186.00M
-138.00M
Net interest expenses
-188.00M
-191.00M
-186.00M
-138.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.54B
1.00B
408.00M
1.45B
Gain or loss from assets sale
-
-8.00M
-12.00M
-69.00M
Upcoming events
AI content may include mistakes. Learn more
Google apps